Tag

Your search for Birth cohort screening returned 12 results.


Exclusive Hepatitis C Interview: Daryl Luster

So my first question is, can you please tell me a little bit about yourself? DARYL LUSTER: Oh, gosh, what’s to tell? I’m 61 this month. Regarding my background, if somebody had said to me 10, even 15 years ago, that I would be involved in health advocacy, I would have said, huh?  No. Really? So it’s been a real shift for me. I come from a business ...

Read More


Exclusive HCV Interview: Lucinda K Porter, RN

Please tell me a little bit about yourself. LUCINDA: I was a patient who was infected with hepatitis C in 1988, and I turned that into an opportunity to learn more about hepatitis C. I have been working in this field since 1997. Along the way, I worked at Stanford Medical Center in their Hepatology Division. I’ve also done a lot of writing since the late ’90s, ...

Read More


Interventions in the HCV care continuum

New systematic review in the journal International Journal of Drug Policy discusses published evidence-based interventions to enhance assessment, treatment, and adherence in the chronic Hepatitis C care continuum. Authors note that primary care settings represent key opportunities for HCV care linkage interventions, often within clinics that have prolonged engagement ...

Read More


Special Interview on HCV: Dr. S. Wiktor of WHO

Thank you for agreeing to participate in this special interview on HCV. What do you see as the biggest global challenges in the diagnosis, screening, and treatment of hepatitis C? Dr. Wiktor: The landscape is changing very quickly and it is being driven by remarkable progress in the development of direct-acting antiviral therapies for hepatitis C. We hear ...

Read More


EASL Congress HCV Interview: Dr E. Lebovics

Regarding studies that are ongoing, what are you most excited about seeing at EASL? The results of which studies and what types of studies? Dr. Lebovics: Well, now that we are able to eliminate hepatitis C with all oral regimens in about 95% of standard patients, one area of great interest is extending our currently available regimens to special populations, ...

Read More


EASL Pre-Congress HCV Interview: Dr R. Brown

Is there any data that is going to be presented at EASL that you’re really excited about? Are there any research studies that are going on right now that you’re really excited about? Dr. Brown: Right now we have two excellent FDA approved options for our genotype 1 Hepatitis C patient, but we have issues with patients who are not genotype 1, or those who have ...

Read More


EASL Pre-Congress HCV Interview: Dr P. Gaglio

What are your thoughts on birth cohort screening for hepatitis C? Should it be mandated by law? Dr. Gaglio: Sure, well I think that birth-cohort screening is an absolutely forward progress in terms of the screening of Hepatitis C, largely due to the fact that risk-based screening has been very ineffective. So, [birth-cohort screening] has been mandated by law and ...

Read More


Urgent need for birth cohort hepatitis C testing

Study highlights urgent need to implement recent CDC and USPTF birth cohort Hepatitis C testing recommendations in the routine clinical environment While there have been many recent notable advances in the treatment of hepatitis C, these advances can only help those individuals who are tested and identified. Unfortunately, the proportion of unidentified anti-HCV ...

Read More


Real-life HCV management in US urban center

Study provides a “real-life” snapshot of how HCV infection is being addressed in a major US urban center Acute hepatitis C infection is asymptomatic in 60-70% of individuals. Many people only learn that they are HCV-positive decades later, after their disease has progressed to cirrhosis, hepatocellular carcinoma, or liver failure. Unfortunately, 50-75% of ...

Read More


HCV linkage-to-care for baby boomers in the ED

Recent study highlights the necessity of providing HCV screening and linkage-to-care to baby boomer patients in the emergency department HCV-infected individuals are more likely to use the emergency department (ED) for care than any other healthcare venue. HCV antibody prevalence appears to be between 4-18% in the general ED population. Frequent users of the care ...

Read More